(Source: MARKETWIRE)
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that
executive management will participate in the Oppenheimer Healthcare
Conference to be held November 3 - 4, 2009 at the Waldorf Astoria in
New York City. Mr. Armando Anido, Chief Executive Officer and
President, is scheduled to present an overview of the Company and its
product pipeline at 10:50 a.m. EST on Wednesday, November 4, 2009.
To listen to the audio web cast of the presentation during or after
the event, please visit: http://www.auxilium.com. The replay will be
available for ninety days after the event.
About Auxilium
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical
company with a focus on developing and marketing to urologists,
endocrinologists, orthopedists and select primary care physicians.
Auxilium markets Testim(R) 1%, a topical testosterone gel, for the
treatment of hypogonadism through its approximately 190-person sales
and marketing team. Auxilium has five projects in clinical
development. XIAFLEX(TM) (collagenase clostridium histolyticum),
formerly referred to as AA4500, has completed phase III clinical
trials for the treatment of Dupuytren's disease, and the biologics
license application is under review at the FDA for the treatment of
Dupuytren's disease. XIAFLEX is in phase IIb of development for the
treatment of Peyronie's disease and is in phase II of development for
treatment of Frozen Shoulder syndrome (Adhesive Capsulitis).
Auxilium's transmucosal film product candidate for the treatment of
overactive bladder (AA4010) and its fentanyl pain product using its
transmucosal delivery system are in phase I of development. The
Company is currently seeking a partner to further develop these
product candidates. Auxilium has rights to additional pain products
and products for hormone replacement and urologic disease using its
transmucosal film delivery system. Auxilium also has options to all
indications using XIAFLEX for non-topical formulations. For
additional information, visit http://www.auxilium.com.
Safe Harbor Statement
This release contains "forward-looking-statements" within the meaning
of The Private Securities Litigation Reform Act of 1995, including
statements regarding the Company's intention to present at the
Oppenheimer 20th Annual Healthcare Conference, and products in
development for the treatment of Dupuytren's contracture, Peyronie's
disease and Frozen Shoulder Syndrome and for pain, hormone
replacement and urologic disease.
